Intellectual Property and Regulatory Law

SMi Group

November 7, 2017

Generic drug manufacturers can pose major financial threats to the companies that invent and develop the copied drugs both domestically and internationally. Even after a pharmaceutical company is granted patent protection on its products, there are other concerns about generics that Big Pharma face from abroad.

Intellectual property, consists largely of ideas and knowledge, it is a vital element of parallel trade. Arnold & Porter Kaye Scholer LLP’s, Patent Litigation & Strategy Partner, Christopher Stothers will take the stage at next year’s 12th annual Parallel Trade conference, in Central London, to address the evolving IPR strategy requiring a better focus and approach in the coming era, within the pharmaceutical industry. Christopher’s presentation will examine the following topics:

IP developments in the EU and USA

Regulatory issues

Brexit focus: news and expectations

Christopher is a recognised expert in parallel trade, with a focus on the pharmaceutical sector – his 2007 textbook, “Parallel Trade in Europe: Intellectual Property, Competition and Regulatory Law,” has been cited by the UK Supreme Court. Christopher is also an experienced litigator on cross-border patent disputes, other types of intellectual property, antitrust, pharmaceutical regulation, EU law and commercial disputes. He has taken cases before the First Tier Tribunal, the Upper Tribunal, the Patents County Court, the High Court, the Court of Appeal, the House of Lords, the Supreme Court, the European Patent Office, and the European Court of Justice.